Direct coronary stenting through left and right internal mammary artery grafts.

J Invasive Cardiol

Cardiac Catheterization Laboratory, Catharina Hospital, Eindhoven, The Netherlands.

Published: July 2002

We describe a case of successful direct coronary stenting of two tight lesions, one at the site of the left internal mammary artery (LIMA) graft anastomosis with left anterior descending coronary artery and the other at the site of the anastomosis between the right internal mammary artery (RIMA) graft and the right coronary artery. To our knowledge, this is the first reported case of successful direct stent implantation through the LIMA and RIMA.

Download full-text PDF

Source

Publication Analysis

Top Keywords

internal mammary
12
mammary artery
12
direct coronary
8
coronary stenting
8
left internal
8
case successful
8
successful direct
8
coronary artery
8
artery
5
stenting left
4

Similar Publications

Background: A significant proportion of false positive recalls of mammography-screened women is due to benign breast cysts and simple fibroadenomas. These lesions appear mammographically as smooth-shaped dense masses and require the recalling of women for a breast ultrasound to obtain complementary imaging information. They can be identified safely by ultrasound with no need for further assessment or treatment.

View Article and Find Full Text PDF

Background: The deep inferior epigastric perforator (DIEP) flap is currently the gold standard for autologous breast reconstruction. In cases where the DIEP is contraindicated, the profunda artery perforator (PAP) flap is now the preferred second-line option in our institution. The PAP flap poses unique challenges to the reconstructive surgeon, especially in Asian women with low body mass index (BMI).

View Article and Find Full Text PDF

Locoregional treatments of metastatic internal mammary node following neoadjuvant chemotherapy.

Chin Med J (Engl)

January 2025

Department of Breast Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong 510060, China.

View Article and Find Full Text PDF

Purpose: The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial.

Methods: Randomized clinical trials were conducted at 12 centers in China from August 22, 2017, to September 24, 2021, and the final follow-up date was August 25, 2023. Patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who had no previous systemic therapy in the metastatic setting were enrolled.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!